Page 161 - Programme book for The International Liver Congress 2015, EASL ILC 2015

P0232 REDUCED TRANSCRIPTIONAL RESPONSIVENESS ePOSTERS
P0233 TOWARDS THE ANTI-CANCER DRUG IRINOTECAN IS
P0234 MEDIATED BY A COMMON UGT1A HAPLOTYPE
Sandra Kalthoff*, Anja Winkler, Christian Strassburg, Germany
P0235
P0236 MICRORNA-210 ENHANCES TUMOR ANGIOGENESIS BY
P0237 TARGETING FGFRL1 IN HEPATOCELLULAR CARCINOMA
Tian Xia,Yun Yang, Gaiyun Li, Jin Zhang,Yuan Yang,Yu Wei*, Ke Lan,
Weiping Zhou, France

A TGF-BETA GENOMIC SIGNATURE IN INTRAHEPATIC
CHOLANGIOCARCINOMA HIGHLIGHTS A NOVEL
LONG NON CODING RNA LOCATED IN THE NUCLEAR
PARASPECKLES OF TUMOR CHOLANGIOCYTES
Aude Merdrignac*, Gaëlle Angenard, Damien Bergeat, Alain Fautrel,
Bruno Turlin, Karim Boudjema, Bruno Clément, Laurent Sulpice,
Cedric Coulouarn, France

PROTEIN N-TERMINAL ACETYLATION INHIBITION AS A
NOVEL THERAPEUTIC TARGET FOR HEPATOCELLULAR
CARCINOMA
Delia D’Avola*, Leire Neri, Marta Lasa, Mercedes Iñarrairaegui,
José Ignacio Herrero, Jesus Prieto, Bruno Sangro, Rafael Aldabe, Spain

ROLE OF YAP SIGNALLING DEREGULATION IN THE
GENETIC SUSCEPTIBILITY TO HEPATOCARCINOGENESIS,
AND STEMNESS AND AGGRESSIVITY OF LIVER CANCER
Rosa Maria Pascale, Gavinella Latte*, Roberta Pola, Lucia Daino,
Maria A. Seddaiu, Maria M. Simile, Maria I. Demartis, Italy

HEPATOCELLULAR CARCINOMA: APPLIED GENOMICS TO
DIAGNOSTIC AND PERSONALIZED THERAPY
Susana Llerena*, Nuria García, Carlos Rodriguez de Lope,
Laura Cereceda, Luis Martin, Carlos Lopez, Carmen Cagigas,
Federico Castillo, Ainara Azueta, Miguel Angel Piris, Jose Pedro Vaqué,
Javier Crespo, Spain

Vienna, Austria • April 22–26, 2015 161